- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites - The cardioprotectant dexrazoxane as a model case2011 | Faculty of Pharmacy in Hradec Králové
- Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity2020 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo2015 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové